Using epidemiology and archaeology to unearth new drug targets for rheumatoid arthritis therapy.
Epidemiological and archaeological evidence suggests that RA could be a consequence of enhanced immunity to Mycobacterium tuberculosis, and that by understanding this connection, new RA drug targets may be uncovered.